Tissue Repair Ltd (AU:TRP) has released an update.
Tissue Repair Limited reported significant progress in the second quarter of 2024, with their chronic wound treatment TR987® on track for Phase 3 clinical trials and their aesthetic product TR Pro+TM seeing a 130% revenue growth from the previous quarter. The company maintains a strong cash position of $16.4 million, with net cash outflows of $1.549 million mainly due to development and commercialization efforts. Looking ahead, the company expects increased cash outflows aligned with the advancement of their clinical program and product commercialization.
For further insights into AU:TRP stock, check out TipRanks’ Stock Analysis page.
